136522-33-3

Basic information

• Product Name: (1S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-Cyclopentene-1- methanol
• Synonyms: (1S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-Cyclopentene-1- methanol;((1S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol
• CAS NO: 136522-33-3
• Molecular Formula: C₁₁H₁₂ClN₅O
• Molecular Weight: 266
• EINECS: 1308068-626-2
• Mol File: 136522-33-3.mol
• Article Data: 22

Chemical Properties

• Melting Point: 208℃
• Boiling Point: 572.0±60.0 °C(Predicted)
• Appearance: /
• Density: 1.74
• Storage Temp.: 2-8°C
• PKA: 14.86±0.10(Predicted)
• CAS DataBase Reference: (1S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-Cyclopentene-1- methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-Cyclopentene-1- methanol(136522-33-3)
• EPA Substance Registry System: (1S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-Cyclopentene-1- methanol(136522-33-3)

Safety Data

• Hazardous Substances Data: 136522-33-3(Hazardous Substances Data)

Usage

General Description

The chemical compound "(1S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-Cyclopentene-1- methanol" is a complex molecule with a cyclopentene ring and a purine group. The compound contains an amino group and a chlorine atom attached to the purine ring. It also features a alcohol functional group attached to the cyclopentene ring. (1S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-Cyclopentene-1- methanol is a chiral molecule, with the (1S,4R) configuration indicating the stereochemistry of the molecule. It is likely to have biological activity due to the presence of the purine group and may be used in pharmaceutical research and drug development.

Upstream product

• 10310-21-1 2-Amino-6-chloropurin 
• 159418-20-9 (4aR,7aR)-4,4a,5,7a-Tetrahydro-cyclopenta[1,3]dioxin-2-one 
• 178327-18-9 [3(1R,2R),4S]-4-benzyl-3-(2-hydroxycyclopent-3-enecarbonyl)oxazolidin-2-one 
• 178327-17-8 [3(2S,4R),4S]-3-(2-allyl-3-hydroxypent-4-enoyl)-4-benzyloxazolidin-2-one 
• 172015-79-1 ((1S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol hydrochloride 
• 1026616-09-0 6-chloro-9-((1R,4S)-4-((triisopropylsilyloxy)methyl)cyclopent-2-enyl)-9H-purin-2-amine 
• 141271-13-8 (1S,4R)-4-(<2'-amino-6'-chloro-5'-<(4''-chlorophenyl)azo>pyrimidin-4'-yl>amino)cyclopent-2-enylmethanol 
• 122-51-0 orthoformic acid triethyl ester 
• 141271-12-7 (1S, 4R)-(4-(2,5-diamino-6-chloro-4-pyrimidinyl)amino)-2-cyclopenten-1-methanol 
• 229613-83-6 (–)-methyl (1S,4R)-4-aminocyclopent-2-ene-1-carboxylate hydrochloride 
• 130931-84-9 (-)-(1S,4R)-4-aminocyclopent-2-ene-1-carboxylic acid hydrochloride 
• 141271-11-6 (-)-(1S,4R)-4-<(2'-amino-6'-chloropyrimidin-4'-yl)amino>-cyclopent-2-enylmethanol 
• 136522-35-5 (1R,4S)-1-amino-4-hydroxymethyl-2-cyclopentene 
• 79200-56-9 (-)-2-azabicyclo[2.2.1]hept-5-en-3-one 

Downstream Products

• 136470-78-5 abacavir 
• 124752-25-6 (1α,4α)-4-(2,6-Diamino-9H-purin-9-yl)-2-cyclopentenyl-carbinol 

Relevant articles and documents

An asymmetric synthesis of (-)-carbovir

Enantioselective deprotonation of trans-4-t-butyldimethylsiloxymetyl-1,2-epoxycyclopentane (trans-4) by a chiral lithium amide, lithium (S)-2-(pyrrolidin-1-ylmethyl)pyrrolidide (1), afforded (1S,4S)-trans-4-t-butyldimethylsiloxymethyl-2-cyclopenten-1-ol (trans-7) in 83% ee. Alcohol trans-7 was easily transformed to (-)-carbovir, an anti-HIV carbocyclic nucleoside.

Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol

The present invention relates to novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1 -methanol of Formula I or solvates or hydrates thereof, wherein M represents hemimalonate, malonate, hemioxalate, oxalate, hydrobromide, dihydrobromide, hemimaleate, maleate.

PROCESS FOR THE PREPARATION OF (1S, 4R) -CIS-4-‘2-AMINO-6CHLORO-9H-PURIN-9-YL!-2-CYCLOPENTENE-1-METHANOL

A process for preparing a chloropurine compound of formula (I) or a derivative thereof, which comprises ring closure of the compound of formula (VII) or a derivative thereof in the presence of catalytic acid and at least one equivalent of a formate derivative.